https://www.selleckchem.com/products/gw4869.html
As more individuals with ALD are identified at birth, it remains uncertain if availability of matched donors, transplant (and potentially, gene therapy) centers, and specialists may affect the timely treatment of these individuals. As these promising gene therapy trials and newborn screening transform the clinical management and outcomes of ALD, there will be an increasing need for the endocrine management of pre-symptomatic and subclinical adrenal insufficiency. © Endocrine Society 2020. All rights reserved. For permissions, please e-ma
Like
Comment
Share
